Influence of vaccine prevention of pneumoccocus conjugated vaccine on mortality in patients with COPD

Abstract

Objective: to analyze the effectiveness of vaccine prophylaxis 13-valence conjugated pneumococcal vaccine (PCV13) by the effect on mortality in COPD patients.

Material and Methods: 362 male patients with COPD: group 1 - 150 patients vaccinated with PCV13, group 2 - 212 people unvaccinated. The observation period is 7 years. The average age of the studied groups was 68.56 (95% CI; 62.46-74.27) years. Mortality per 1000 vaccinated / unvaccinated was calculated patients. The structure of mortality in the age groups under 65 years old and over 65 is analyzed years. For vaccine prophylaxis, 13-valent conjugated vaccine pneumococcal was used.

Results: patients in both groups were statistically comparable: up to 65 years old - 31% in the first group and 32% in the second, over 65 years old - 69% in the group PCV13 and 68% in the group of unvaccinated. During the observation period among vaccinated was 6 deaths were registered, mortality rate - 39.9. In the group of unvaccinated patients there were 17 deaths, the mortality rate was 80.2, which is statistically significantly higher in comparison with the 1st group. Cardiovascular diseases (40%) and COPD progression (47%) predominated in the mortality structure, especially in unvaccinated patients older than 65 years (p<0.05).

Conclusions: 1. An increase in age is associated with an increase in mortality, regardless of vaccine prophylaxis. 2. The main causes of mortality in both observation groups are cardiovascular disease and the progression of COPD however level the mortality rate in the unvaccinated group is significantly higher. 3. The use of PCV13 vaccination significantly reduces mortality, especially due to COPD.